Pseudomonas aeruginosa and beta-lactam antibiotics at the time of Europe;Pseudomonas aeruginosa et bêta-lactamines à l'heure de l'Europe

Pathologie Biologie

Volumn 56, Issue 7-8, 2008, Pages 435-438

  Cavallo, J D ^a,b   Merens A ^a,b  

^a SERVICE D ENDOCRINOLOGIE   (France)

^b 2ème Centre Médical des Armées   (France)

Author keywords

lactams; Breakpoint; CA SFM; EUCAST; Pseudomonas aeruginosa

Indexed keywords

AZTREONAM; BETA LACTAM; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; IMIPENEM; MEROPENEM; PENICILLIN G; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TICARCILLIN; TIMENTIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; DEVICE; EUROPE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; QUANTITATIVE ANALYSIS;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; BETA-LACTAMS; CARBAPENEMS; CEPHALOSPORIN RESISTANCE; CEPHALOSPORINS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; MICROBIAL SENSITIVITY TESTS; MONOBACTAMS; PENICILLIN RESISTANCE; PENICILLINS; PSEUDOMONAS AERUGINOSA;

EID: 56949096206     PISSN: 03698114     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.patbio.2008.07.028     Document Type: Article

References (9)

1. Leegard T.M., Caugant D.A., Froholm L.O., and Hoiby E.A. Apparent differences in antimicrobial susceptibility as a consequence of national guidelines. Clin Microbiol Infect 6 (2000) 290-293
2. Khalmeter G., Brown D.F.J., Goldstein F.W., MacGowan A., Mouton J., Osterlund A., et al. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J Antimicrob Chemother 52 (2003) 145-148
3. European Committee for Antimicrobial Susceptibility Testing. Determination of antimicrobial susceptibility test breakpoints. Clin Microbiol Infect 2000; 6:570-2.
4. DeRyke C.A., Kuti J.L., and Nicolau D.P. Reevaluation of current susceptibility breakpoints for Gram-negative rods based on pharmacodynamics assessment. Diag Microbiol Infect Dis 58 (2007) 337-344
5. Mouton J.W., Punt N., and Vinks A.A. Concentration-effet relationship of cefatzidime explains why the time above MIC is 40 % for a static effect in vivo. Antimicrob Agents Chemother 51 (2007) 3449-3451
6. Frei C., Wiederhold N.P., and Burgess D.S. Antimicrobial breakpoints for Gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation. J Antimicrob Chemother 61 (2008) 621-628
7. Tam V.H., Gamez E.A., Weston J.S., Geranrd L.N., Lacorro M.T., Caeiro J.P., et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam : implications on the appropriateness of the resistance breakpoint. Clin Infect Dis 46 (2008) 862-867
8. Jacobs M.R., Koeth L.M., and Appelbaum P.C. Use of appropriate breakpoints in antimicrobial surveillance studies. Clin Infect Dis 35 (2002) 1446-1448
9. Joly-Guillou M-L, Cavallo J-D, Chomarat M, Dubreuil L, Maugein J, Muller-Serieys C, et al. Comparative activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1118 bacteria involved in hospital infections: a French multicenter study. European Congress and Clinical Microbiology and Infectious Diseases, 2008 April 19-22; Barcelona. Poster P612.